Diabetic Macular Edema (DME) Market Report 2026

The diabetic macular edema (dme) market size has grown steadily in recent years. It will grow from $4.88 billion in 2025 to $5.09 billion in 2026 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to rising prevalence of diabetic eye disease, limited early detection practices, increasing vision impairment cases, reliance on hospital-based ophthalmology care, growth in diabetes duration.

The diabetic macular edema (dme) market size is expected to see steady growth in the next few years. It will grow to $6 billion in 2030 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to advancements in biologic therapies, expansion of ai-driven eye screening, growth of specialty eye clinics, increasing awareness of diabetic eye complications, aging diabetic population. Major trends in the forecast period include increasing adoption of anti-vegf therapies, rising use of advanced retinal imaging technologies, expansion of early diagnosis and monitoring programs, growing focus on vision preservation treatments, integration of AI-based ophthalmic screening.

The rising prevalence of diabetes is expected to propel the growth of the diabetic macular edema (DME) market in the coming years. The increase in diabetes prevalence is driven by factors such as sedentary lifestyles, unhealthy eating habits, growing obesity rates, aging populations, and genetic predisposition. Diabetes leads to diabetic macular edema by damaging retinal blood vessels, causing fluid leakage into the macula and resulting in swelling. For instance, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research organization, reported that more than half a billion people worldwide were living with diabetes, with projections indicating this number could exceed 1.3 billion by 2050. Therefore, the rising prevalence of diabetes is driving the growth of the diabetic macular edema market.

Major companies operating in the diabetic macular edema market are increasingly focusing on adopting sustained-delivery implant technologies, such as refillable ocular implants, to improve treatment longevity, patient adherence, and efficiency in vision management. Refillable ocular implants are surgically placed devices that deliver medication continuously over extended periods, enabling reduced dosing frequency, sustained therapeutic exposure, and lower treatment burden. For instance, in February 2025, F. Hoffmann-La Roche AG, a Switzerland-based biotechnology and pharmaceutical company, received approval for Susvimo (ranibizumab 100 mg/mL delivered through a port delivery system), a refillable ocular implant for treating DME. The implant enables continuous ranibizumab delivery with refill intervals as infrequent as twice a year and demonstrates vision outcomes comparable to monthly intravitreal injections. Susvimo enhances patient compliance, minimizes injection frequency, and supports long-term vision preservation.

In July 2024, Merck & Co Inc, a US-based pharmaceutical company, acquired Eyebiotech Limited for $1.3 billion. This acquisition enables Merck to strengthen its ophthalmology portfolio, expand research capabilities, and gain access to Restoret (EYE-103), a potential treatment for diabetic macular edema and treatment-naive neovascular age-related macular degeneration. Eyebiotech Limited is a UK-based biotechnology company focused on developing innovative therapies in ophthalmology.

Major companies operating in the diabetic macular edema (dme) market are Roche Holding AG, Bayer AG, Novartis AG, Regeneron Pharmaceuticals, Carl Zeiss Meditec AG, Bausch & Lomb, Carl Zeiss AG, Topcon Corporation, Optos plc, Allergan plc, Chengdu Kanghong Pharmaceutical Group, Kodiak Sciences, Opthea Limited, Oxurion NV, Aerie Pharmaceuticals Inc, Coherus BioSciences, KalVista Pharmaceuticals Inc, Araim Pharmaceuticals Inc, Acucela Inc, Antisense Therapeutics Limited, BCN Peptides SA, Ampio Pharmaceuticals Inc, Oculis SA, ThromboGenics NV, EyePoint Pharmaceuticals Inc.

North America was the largest region in the diabetic macular edema (DME) market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic macular edema (dme) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetic macular edema (dme) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the diabetic macular edema market by increasing costs of imported anti-VEGF drugs, retinal imaging systems, and ophthalmic surgical equipment. Hospitals and eye care centers in North America and Europe are most affected due to reliance on imported biologics and imaging devices, while Asia-Pacific faces higher diagnostic infrastructure costs. These tariffs increase treatment expenses. However, they also encourage regional drug manufacturing and localized production of ophthalmic devices.

The diabetic macular edema (dme) market research report is one of a series of new reports that provides diabetic macular edema (dme) market statistics, including diabetic macular edema (dme) industry global market size, regional shares, competitors with a diabetic macular edema (dme) market share, detailed diabetic macular edema (dme) market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic macular edema (dme) industry. This diabetic macular edema (dme) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diabetic macular edema (DME) is a diabetes-related complication that develops when fluid builds up in the macula, the central region of the retina responsible for clear, detailed vision. This swelling results from damaged blood vessels that leak fluid and proteins into retinal tissue, which can cause visual impairment or blindness if not treated. DME is a leading cause of vision loss among people with diabetes and is closely linked to diabetic retinopathy.

The main treatments for diabetic macular edema include anti-VEGF therapy, corticosteroids, laser therapy, and surgical intervention. Anti-VEGF therapy functions by blocking vascular endothelial growth factor (VEGF), a protein that promotes abnormal blood vessel formation and retinal leakage associated with DME. The condition progresses through stages such as early, moderate, and advanced. Patient demographics are classified by age groups including adults, elderly individuals, and children. Routes of administration include intravitreal injection, topical, and systemic methods, and treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The diabetic macular edema (DME) market consists of revenues earned by entities by providing services such as retinal imaging, fluorescein angiography, visual acuity testing, and laser therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetic macular edema market includes sales of ranibizumab, aflibercep, fluocinolone acetonide intravitreal implant, and dexamethasone intravitreal implant. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.